Cinctive Capital Management’s Royalty Pharma RPRX Stock Holding History

Cinctive Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-53,190	Closed	-$1.92M	–	502
2025 Q2	$1.92M	Buy	+53,190	New	+$1.76M	0.1%	222
2022 Q2	–	Sell	-25,000	Closed	-$974K	–	621
2022 Q1	$974K	Buy	+25,000	New	+$982K	0.04%	403
2020 Q3	–	Sell	-28,375	Closed	-$1.38M	–	360
2020 Q2	$1.38M	Buy	+28,375	New	+$1.4M	0.16%	216

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cinctive Capital Management's RPRX Position: Q3 2025 in Review

Cinctive Capital Management sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 53,190 shares — an estimated $1.92M sold.

Cinctive Capital Management first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $1.92M in Q2 2025. 488 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

Cinctive Capital Management reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
Cinctive Capital Management sold 53,190 Royalty Pharma shares in Q3 2025, an estimated $1.92M.
Cinctive Capital Management first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
Cinctive Capital Management's Royalty Pharma position peaked at $1.92M in Q2 2025.
488 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.